A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Trial details
- Registry ID
- NCT06388200
- Drugs studied
- Sub-Retinal Administration of OCU400-301
TrialRedline tracks 2 clinical trials sponsored by Ocugen: 1 Phase 3, 1 Phase 2 / 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200 | Sub-Retinal Administration of OCU400-301 | Active not recruiting | 2027-02-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626 | OCU410ST | Active not recruiting | 2026-09-28Estimated |
Names as written in the registry records.
Before: Recruiting. After: Active not recruiting.
NCT06388200 · Ocugen
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA Measure: Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA. After: Measure: Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control.
Before: Estimated. After: Actual.
Before: 150 participants (planned). After: 140 participants (actual).
Before: 31 Dec 2026. After: 12 Feb 2027.
NCT06388200 · Ocugen
Before: Recruiting. After: Active not recruiting.